Compare PNNT & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNNT | AGEN |
|---|---|---|
| Founded | 2007 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.4M | 274.8M |
| IPO Year | 2007 | 1999 |
| Metric | PNNT | AGEN |
|---|---|---|
| Price | $3.58 | $6.94 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $5.75 | ★ $14.50 |
| AVG Volume (30 Days) | 472.1K | ★ 996.7K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 20.87% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.96 |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | N/A | $107.63 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.14 | ★ $7.15 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $3.19 | $2.71 |
| 52 Week High | $7.06 | $8.85 |
| Indicator | PNNT | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 42.54 | 44.89 |
| Support Level | $3.31 | $2.97 |
| Resistance Level | $3.59 | $8.70 |
| Average True Range (ATR) | 0.09 | 0.53 |
| MACD | -0.03 | -0.21 |
| Stochastic Oscillator | 6.45 | 12.37 |
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.